Sector News

Bayer’s biotech head Jens Vogel says good-bye after 4 years

June 16, 2024
Life sciences

Amid an organizational reset, Bayer’s SVP and Global Head of Biotech Jens Vogel, Ph.D., has hit the exits after four years with the German pharma.

“After more than four years of leading and transforming the global biotech organization at Bayer, it’s time for me to move on and pursue new opportunities!” Vogel wrote in a June 11 LinkedIn post announcing his departure. “For the first time in my career, I am now taking a bit of a break, spending quality time with my family starting with a long trip through southeast Asia, before pursuing a new role.”

Vogel joined Bayer in March 2020, leading the company’s integrated global biotech network, including biologics development, operations and product supply, tech development and strategy functions across sites in the U.S. and Europe. Before that, Vogel had clocked in nearly 11 years at Boehringer Ingelheim across various leadership roles.

While Vogel didn’t cite any broader organizational changes as the reason behind his resignation, his departure comes amid a heavy-handed restructuring at the German pharma. Back in January, Bayer unveiled plans that have ultimately led to the elimination of more than 1,500 roles in the first three months of 2024. About two-thirds of the terminated positions are management roles.

The company generally doesn’t comment on colleagues’ departure decisions, a Bayer spokesperson told Fierce Biotech this morning. However, Bayer’s new Global Head of Biologics Manufacturing Tina Self confirmed in an interview that the head biotech role no longer exists amid Bayer’s redesign.

Self, who stepped into her new role June 1, was most recently vice president and site manager of Bayer Berkeley, a 46-acre site in California. She is also stepping in as the Berkeley campus’ site head, the first female leader to ever take on that role at Bayer.

The organizational redesign includes regrouping teams into “clusters,” with Self helming the “biologics manufacturing capability cluster.”

“We’ve moved from really just a technology base, where everything was aligned around the technology, to a capability base,” Self explained.

The new design for product supply started back in December 2023, Self said. The clusters are meant to bring together people with similar professional backgrounds and reduce bureaucracy and hierarchy within the company. The move is also aimed at boosting agility for the overall organization.

“Overall, our mission is really to provide excellent, cost-effective, reliable and high-quality manufacturing of all the biopharmaceuticals for our patients,” Self summed up.

By Gabrielle Masson


comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach